Helus Pharma is considered a buy as it prepares for the topline results of its Phase 3 trial for HLP003, targeting adjunctive major depressive disorder, expected in the fourth quarter of 2026. The drug uses a unique intermittent dosing model and showed promising Phase 2 results with significant symptom reduction and remission rates. The company has a cash balance of $166.4 million, providing a runway of 12 to 14 months, though dilution risk exists due to high operating costs and a $100 million ATM facility. The investment outlook depends on strong Phase 3 efficacy, safety, and successful financing before a potential new drug application filing in 2028.
Helus Pharma is the subject of this update, with Pluang market data providing context for health-sector stocks. As of Oct 11, 2026 20:21 WIB, 109 of 128 health-sector US stocks rose while 18 fell on Pluang. Notable movers include Recursion Pharmaceuticals Inc (RXRX) at USD 4.36 with a 10.38% increase, Hims and Hers Health Inc (HIMS) at USD 30.92 up 10.19%, and Iovance Biotherapeutics Inc. (IOVA) at USD 14.62 rising 9.84%. Typical hold times range from 0 to 23 days, with mixed buy/sell order activity.
FREELANDER has completed a global validation program for its FREELANDER 8 model, involving over 1,000 test vehicles across 50+ road types worldwide. The tests covered extreme conditions including deserts, rocky terrain, and heavy rain, ensuring durab...
Agree Realty (ADC) is highlighted as a highly attractive Real Estate Investment Trust (REIT) for dividend investors, especially during periods of market instability. The author, Luuk Wierenga, emphasizes ADC's strong dividend strategy and suggests it...
Russia's largest bank, Sberbank, has started a pilot program allowing users to trade Bitcoin, Ether, and Tether (USDT) through its Sberbank Online app. The pilot includes buying, selling, deposits, and withdrawals of these digital assets. Broader cus...
Bitcoin's price rose slightly by 0.31% to $83,090 while the total cryptocurrency market capitalization fell by 3.4% to $2.79 trillion. Other major cryptocurrencies showed mixed results, with Ether up 0.28% and XRP down 0.73%. Market trading volume wa...
Adam Back, CEO of Blockstream, criticized Ethereum's original account-based architecture as flawed and claimed he warned its early developers. However, he has not provided any public evidence of such warnings before Ethereum's 2015 launch. The debate...
